Podcast 1 Dec 2023Ipsen drug gives hope for liver disease patients On the podcast this week, we are looking at recent advances in treating certain liver diseases. Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen, and she discusses a breakthrough treatment for primary biliary cholangitis and cholestatic liver disease. What is primary biliary cholangitis? Primary biliary […] December 1, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 12 Aug 2021 European Biotechs Fire up Deals to Develop Parkinson’s Treatments Last month, European biotechs Ipsen and AC Immune announced multi-million euro deals to acquire or license treatments for Parkinson’s disease. For some experts, this increasing interest in the brain disease with the fastest growing prevalence is long overdue. In July, Swiss company AC Immune bought assets and intellectual property for investigational Parkinson’s vaccines valued at […] August 12, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2020 Ipsen Resumes Phase III Testing for Rare Disease Drug and Abandons Pediatric Trial The French pharmaceutical company Ipsen has restarted the dosing of its treatment for a rare bone disease in a phase III trial after obtaining questionable interim results. At the same time, the company has terminated a phase II trial of the same drug in pediatric patients with a different bone disorder following a partial clinical […] March 31, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email